Nearly 500,000 children in the United States are diagnosed with hemiplegic [cerebral palsy](https://www.withpower.com/clinical-trials/cerebral-palsy) annually, making it a leading cause of severely disabling childhood disability. The rate of hemiplegic cerebral palsy increases with the increasing frequency of perinatal asphyxia and preeclampsia; this rate may further increase as the perinatal screening and treatment of the disease has become more effective.
Recent findings is the first time, in our opinion, to explore the association between risk factors for hemiplegic CP and environmental exposures in the setting of a specific population. Exposure to environmental risk factors at certain times during the gestational period is associated with worse outcomes for infants with hemiplegic CP at age 1 year. Birth at term was protective of both infant and child outcomes.
HCP is a disease with frequent and variable sequelae that can be traced back to lesions in the embryonic brain that impair growth. Children with HCP have multiple disabling conditions along with intellectual disability, motor impairment and sensory dysfunction. They require a multidisciplinary approach to healthcare with physical therapists, speech therapists and social workers leading the treatment team, working along with a multidisciplinary team including paediatric psychiatrists to assess and manage mental health issues.
Hemiplegic cerebral palsy can present clinically as mild motor deficits and psychomotor problems (particularly in older children), but it is possible that subtle motor disturbances may be missed in young children. The degree of hemiplegia is correlated with functional deficits in the paretic (weak or paralyzed side of the body); the use of non-paretic limbs is possible, but may result in altered movement patterns. The hemiparesis and ataxia in children might be indicative of subcortical injury.
Children with hemiplegic [cerebral palsy](https://www.withpower.com/clinical-trials/cerebral-palsy) may have moderate to severe motor and/or intellectual disability. As the severity of their disabilities increases, the range of treatment options increases as well. Children with hemiplegic cerebral palsy may be treated in the same way as healthy children with hemiplegic cerebral palsy. However, hemiplegic cerebral palsy children may have more serious medical issues, which puts them at a higher risk for non-essential medical costs. If not treated, many hemiplegic cerebral palsy children will eventually suffer from spastic quadriplegia, and the most common cause of medical-related death in hemiplegic cerebral palsy children is cancer.
There appears to be little genetic contribution to the early development of CCSP by the traditional criteria of consanguinity and family history. However, given that familiality is higher than 5%, we cannot exclude a role for genes in the etiology of CCSP if familial cases would also be included.
Children aged 5–6 years accounted for the largest proportion of children with hemiplegic cerebral palsy, followed by children aged 7–13 years. Children aged 10–14 years were the only age group with disproportionately low numbers compared with the number of children with hemiplegic cerebral palsy of other ages.
Data from a recent study of this study, particularly the significant effect in the paretic lower limb, suggest the effectiveness of constraining induced movements therapy. A systematic review of research in this area is encouraged to expand the knowledge on the treatment of pediatric hemiplegic cerebral palsy.
Hemiplegic cerebral palsy is a condition that many children with cerebral palsy encounter when they reach the age of 4 to 5 years. The neurological and cognitive consequences of this condition for children, especially the [spastic children, are serious (Cerebral Palsy Association (2011). I-II)]. Cerebral palsy was more prevalent in this [study population]] than in the UK population (13.5% [CVA (11.9% to 14.7%], CVA; (2012) 14–16.3% [CVA (14% to 17%]) and Canada [CVA (2.1% to 4.2%], Canada 11.
Based on the authors' survey of recent literature, there is little evidence to support any evidence-based practices to treatment of hemiplegic CP, and the existing literature has mostly concentrated on the basic neurological, medical, and nursing features of hemiplegic CP. Although the quality of research on the effectiveness of specific treatment approaches (e.g., exercise) has increased lately, the evidence base is still of low quality and warrants further investigation.
This systematic review concludes that CCIMT, administered three times per week for 11 to 20 weeks, is not efficacious in children with hemiplegic CP. However, future research using this technique should continue to address whether there are subgroups of children with hemiplegic CP who benefit from this therapy to no greater than a placebo.